Research Paper Volume 16, Issue 1 pp 389—401
The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients
Figure 7. (A) The sensitivity analysis of the impact of sarcopenia on OS in TAE or TACE treated HCC patients; (B) The sensitivity analysis of the impact of SMI on OS in TAE or TACE treated HCC patients.